List of Excipients in Branded Drug AMBIEN CR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	AMBIEN CR	zolpidem tartrate	21695-319	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	AMBIEN CR	zolpidem tartrate	21695-319	FERRIC OXIDE RED
Rebel Distributors Corp	AMBIEN CR	zolpidem tartrate	21695-319	HYPROMELLOSE

AMBIEN CR Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

AMBIEN CR is an extended-release zolpidem tartrate tablet built around a biphasic release design: an immediate-release component for sleep initiation and a controlled-release component for sleep maintenance. Its excipient platform uses conventional, broadly available pharmaceutical materials, which limits supply-chain barriers but leaves room for commercial opportunities in generic design, excipient substitution, contract development, and manufacturing optimization. FDA-approved generic zolpidem extended-release products have reduced the exclusivity value of the branded formulation, while formulation know-how remains relevant for reliable dissolution, scale-up, and regulatory approval.

What excipients are used in AMBIEN CR?

AMBIEN CR contains zolpidem tartrate and a conventional oral solid-dose excipient system. The FDA labeling identifies the following inactive ingredients:

Excipient	Likely formulation function
Lactose monohydrate	Diluent and compression aid
Microcrystalline cellulose	Diluent, compactibility enhancer and matrix support
Hypromellose	Hydrophilic release-control polymer and binder
Sodium starch glycolate	Superdisintegrant for immediate release
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Titanium dioxide	Opacifier and colorant
Polyethylene glycol	Film-coating plasticizer
FD&C Yellow No. 6 aluminum lake	Film-coating colorant

The inactive-ingredient list is reported in the FDA-approved prescribing information for AMBIEN CR and in the corresponding DailyMed labeling.[1,2]

The commercial significance lies in the combination rather than in any single excipient. AMBIEN CR uses standard excipients that are available from multiple qualified suppliers. The technical challenge is controlling the interaction among the release polymer, disintegrant, compression force, tablet geometry, coating process and dissolution profile.

How does the AMBIEN CR release mechanism work?

AMBIEN CR uses a two-stage release profile. The first portion of zolpidem is released rapidly to support sleep onset. The second portion is released more slowly to maintain drug exposure during the night.

The formulation strategy is commercially important because it requires simultaneous control of:

• Initial drug release.
• Delayed or extended release from the second tablet phase.
• Tablet integrity during handling.
• Consistent dissolution across the manufacturing scale.
• Acceptable pharmacokinetic exposure.
• Resistance to dose dumping under relevant test conditions.

Hypromellose is the principal release-control excipient. Upon hydration, it forms a polymeric gel layer that slows drug diffusion and matrix erosion. Microcrystalline cellulose supports tablet structure and compression. Sodium starch glycolate promotes rapid breakup of the immediate-release portion. Magnesium stearate and colloidal silicon dioxide support manufacturability but can affect wetting, hardness and dissolution when used at excessive levels.

The product’s commercial differentiation is therefore based on release architecture and performance rather than on the novelty of its individual excipients.

What formulation patents protect AMBIEN CR?

Public patent records associate AMBIEN CR with patents covering modified-release zolpidem formulations and related dosage-form technology. US Patent No. 6,514,531 is commonly identified with controlled-release zolpidem technology associated with the product.[3]

Patent protection in this area generally can cover:

1. A bilayer or multiphase tablet containing immediate-release and extended-release zolpidem.
2. Specific ratios of immediate-release and controlled-release drug.
3. Hydrophilic polymer matrices using hypromellose or related polymers.
4. Dissolution profiles.
5. Tablet structures and manufacturing processes.
6. Methods of treating insomnia with extended-release zolpidem.

The commercial relevance of these claims depends on the currently listed Orange Book patents, patent-term adjustment, terminal disclaimers, litigation history and whether a generic applicant has obtained a license or prevailed in a Paragraph IV dispute. Patent expiration should be confirmed against the current FDA Orange Book and USPTO records before relying on a launch date.[4,5]

How strong is the AMBIEN CR patent estate?

The estate is weaker against conventional generic substitution than it was during the product’s early commercial life because the formulation uses well-known excipients and generic manufacturers have had time to develop alternative extended-release designs.

Patent strength is higher where claims require:

• A defined two-phase release profile.
• Narrow dissolution limits.
• Specific polymer-to-drug ratios.
• Structural features that are difficult to avoid without changing the pharmacokinetic profile.
• Manufacturing parameters linked to the final dosage form.

Patent strength is lower where claims rely on:

• Broad use of hypromellose.
• Generic references to extended release.
• Conventional excipient combinations.
• Functional language that can be met through multiple formulation approaches.

A design-around can use a multilayer tablet, coated multiparticulates, a reservoir system, a different hydrophilic polymer, or a combination of immediate-release and delayed-release granules. The applicant must still demonstrate pharmaceutical equivalence or otherwise satisfy the applicable FDA pathway.

What is the FDA and Orange Book status of AMBIEN CR?

AMBIEN CR was approved by the FDA under NDA 021774 in 2005 for insomnia characterized by difficulty with sleep onset and sleep maintenance.[1] The active ingredient is zolpidem tartrate, a nonbenzodiazepine hypnotic acting at the GABA-A receptor complex.

The relevant regulatory structure is:

Item	Status
Brand	AMBIEN CR
Active ingredient	Zolpidem tartrate
Dosage form	Extended-release tablet
FDA application	NDA 021774
Regulatory pathway for generics	ANDA
Reference-product category	Small-molecule drug
Biosimilar pathway	Not applicable
Key regulatory issue	Demonstration of pharmaceutical equivalence and bioequivalence

AMBIEN CR is not a biologic, so biosimilar competition is not relevant. Competition occurs through ANDA-approved generic zolpidem extended-release products.

The Orange Book determines which patents and exclusivity periods are relevant to ANDA certification. Product-specific listings can change as patents expire, delist, or become legally irrelevant. A current Orange Book review is required for transaction, launch or litigation decisions.[4]

When did AMBIEN CR lose exclusivity?

AMBIEN CR’s commercial exclusivity declined in stages rather than ending on a single date. The product faced the standard erosion associated with:

• Expiration of regulatory exclusivity.
• Expiration or weakening of listed formulation patents.
• Approval of generic zolpidem extended-release ANDAs.
• Settlement or license arrangements involving generic applicants.
• Therapeutic substitution within the broader insomnia market.

The first meaningful generic-entry question concerns approval and launch of zolpidem extended-release tablets, not generic immediate-release zolpidem. Immediate-release zolpidem products do not replicate the AMBIEN CR release profile and compete on a different clinical and commercial basis.

Because patent term and litigation outcomes can alter effective launch timing, the legally operative date is the date on which a generic applicant is permitted to market, not simply the nominal expiration date shown for an individual patent.

Which companies challenge AMBIEN CR through generic products?

Generic competition has come from ANDA applicants and manufacturers active in the U.S. extended-release hypnotic market. Public FDA records identify generic zolpidem tartrate extended-release tablets from multiple manufacturers over time, including companies such as Mylan, Teva and other abbreviated-application sponsors.[6]

The competitive field should be separated into three groups:

Competitor type	Product relevance
Generic zolpidem extended release	Direct AMBIEN CR substitute
Generic zolpidem immediate release	Different release profile and lower-cost alternative
Branded insomnia therapies	Therapeutic substitutes, including orexin antagonists and sedating antidepressants

A company evaluating entry should distinguish approval from commercial launch. An ANDA may be approved but remain unmarketed because of patent settlements, manufacturing limitations, supply economics or a lack of commercial priority.

What excipient opportunities exist for AMBIEN CR generics?

The highest-value opportunity is not a novel excipient. It is a robust formulation platform that delivers equivalent performance with lower manufacturing cost and lower patent exposure.

1. Polymer substitution

Potential substitutes for hypromellose include other controlled-release polymers, such as:

• Hydroxypropyl cellulose.
• Polyethylene oxide.
• Carbomers.
• Ethylcellulose in a matrix or coating system.
• Methacrylate copolymers in multiparticulate systems.

The main development risk is that polymer substitution changes hydration, gel strength, erosion rate and food-effect behavior. A new polymer system may require substantial dissolution and pharmacokinetic work.

2. Direct-compression optimization

Microcrystalline cellulose, lactose and colloidal silicon dioxide create a familiar direct-compression platform. Manufacturers can reduce cost by optimizing:

• Excipient grade.
• Particle-size distribution.
• Bulk density.
• Lubrication time.
• Compression force.
• Tablet press speed.
• Granulation moisture.

The objective is to maintain hardness and friability while preventing delayed release from becoming too slow or immediate release from becoming incomplete.

3. Coating-system substitution

The polyethylene glycol and titanium dioxide coating system is not inherently unique. A generic manufacturer may use an alternative film-coating system if it preserves tablet appearance, stability, mechanical protection and dissolution performance.

Commercial opportunities exist for coating suppliers that can offer:

• Lower-cost ready-to-use coating systems.
• Lower process temperature.
• Reduced coating weight.
• Improved color matching.
• Better moisture protection.
• Consistent coating on multilayer tablets.

4. Lactose-free or low-lactose positioning

The labeled formulation contains lactose monohydrate. A lactose-free alternative could have commercial value for selected patients or markets, although lactose sensitivity is not equivalent to a general contraindication. Mannitol, dibasic calcium phosphate or alternative cellulose-based diluents could be evaluated, subject to compression and dissolution requirements.

5. Modified-release platforms

A generic applicant can consider alternatives to a conventional matrix tablet:

• Bilayer tablets.
• Coated drug-layered beads.
• Multiparticulate capsules.
• Osmotic or membrane-controlled systems.
• Immediate-release plus delayed-release granules.

These designs may create additional development expense but can reduce dependence on claims directed to a particular tablet architecture.

What manufacturing and intellectual-property barriers affect entry?

The core barrier is bioequivalence for a modified-release product. A formulation can match the labeled excipient list and still fail because of differences in:

• Cmax.
• AUC.
• Tmax.
• Food effect.
• Nighttime concentration profile.
• Dose dumping.
• In vitro dissolution.

The principal manufacturing risks include segregation between immediate-release and controlled-release components, variation in polymer hydration, tablet-layer weight drift, over-lubrication and coating defects.

The principal IP risks include:

• Patent claims covering the release profile.
• Claims directed to multilayer tablet construction.
• Method-of-use claims for sleep-maintenance treatment.
• Process claims tied to matrix formation.
• Litigation triggered by Paragraph IV certification.

For a generic applicant, the preferred strategy is usually a formulation that can support a Paragraph III or non-infringement position while maintaining a commercially efficient manufacturing process.

What Paragraph IV and litigation risks apply?

An ANDA applicant that believes a listed patent is invalid, unenforceable or not infringed may file a Paragraph IV certification. The brand holder can then bring an infringement action within the statutory period, potentially triggering a 30-month stay of final FDA approval under the Hatch-Waxman framework.[7]

For AMBIEN CR, the litigation value of a listed patent depends on:

• Remaining patent term.
• Claim scope.
• Whether the patent covers the marketed formulation or only a narrow embodiment.
• Whether a generic design can avoid the asserted claims.
• The commercial value of an early launch.
• Settlement terms, including licensed entry dates and restrictions.

Any settlement may alter the practical launch date even when the nominal patent expiration date remains unchanged. A patent review should therefore include district-court dockets, Federal Circuit decisions, FDA approval letters and settlement-related disclosures.

How does AMBIEN CR compare with competing insomnia drugs?

Product category	Release strategy	Generic risk	Main commercial distinction
AMBIEN CR	Immediate plus extended release	High	Sleep initiation and maintenance
Immediate-release zolpidem	Rapid release	Very high	Lower-cost sleep-onset treatment
Eszopiclone	Immediate release	High	Broader sleep-maintenance positioning
Orexin antagonists	Receptor antagonism	Lower for newer brands	Different mechanism and longer exclusivity
Melatonin-receptor products	Circadian pathway	Variable	Different patient and safety profile

AMBIEN CR’s primary commercial vulnerability is substitution with cheaper immediate-release zolpidem. Its primary strategic advantage is a differentiated release profile that addresses both sleep onset and sleep maintenance.

What commercial opportunities remain?

The strongest opportunities are:

1. Generic or authorized-generic supply in markets with limited competition.
2. Contract development of modified-release zolpidem tablets.
3. Excipient-grade optimization for lower-cost manufacturing.
4. Lactose-free or region-specific formulations.
5. Multiparticulate or alternative controlled-release designs.
6. Private-label supply for pharmacy and hospital channels.
7. Technology licensing for dissolution-controlled matrix systems.
8. Manufacturing transfers using globally available excipient grades.

Revenue exposure for the originator depends on remaining net sales, generic price erosion and payer substitution. Revenue exposure for a generic entrant depends on launch timing, number of approved competitors, channel access and the ability to maintain supply during demand shifts.

Key Takeaways

• AMBIEN CR is a biphasic extended-release zolpidem tartrate tablet.
• Its principal excipients are conventional materials, including hypromellose, lactose monohydrate, microcrystalline cellulose and sodium starch glycolate.
• The formulation challenge is controlling the release profile, not sourcing rare excipients.
• Generic competition is governed by ANDA approval, Orange Book patents and Paragraph IV litigation.
• Biosimilar risk does not apply because zolpidem is a small-molecule drug.
• The best formulation opportunities involve polymer substitution, multilayer or multiparticulate design, coating optimization and cost-efficient scale-up.
• A current Orange Book and litigation review is necessary before setting a launch or licensing date.

FAQs About AMBIEN CR Excipient and Generic Strategy

Can hypromellose be replaced in a generic AMBIEN CR formulation?

Yes. Alternative hydrophilic or membrane-controlled polymers can be evaluated, but replacement may alter dissolution, food effect and pharmacokinetic performance.

Is AMBIEN CR a bilayer tablet?

The product uses an immediate-release and extended-release design. A generic applicant may use a different physical architecture if it demonstrates the required pharmaceutical and bioequivalence performance.

Are AMBIEN CR excipients patent protected individually?

The listed excipients are generally well-known pharmaceutical materials. Patent risk usually arises from the combination, dosage-form architecture, release profile or manufacturing process.

Does AMBIEN CR have biosimilar competition?

No. Zolpidem tartrate is a small-molecule active ingredient. Competition proceeds through the ANDA generic-drug pathway.

What is the most commercially attractive AMBIEN CR formulation opportunity?

A lower-cost extended-release formulation with robust dissolution control, broad excipient sourcing and a credible patent design-around has the strongest commercial potential.

References

1. U.S. Food and Drug Administration. (2005). AMBIEN CR (zolpidem tartrate) extended-release tablets: Prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: AMBIEN CR, zolpidem tartrate extended-release tablets.
3. U.S. Patent No. 6,514,531. (2003). Controlled-release formulation of zolpidem.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. United States Patent and Trademark Office. (n.d.). Patent Center and patent term information.
6. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Zolpidem tartrate extended-release tablets.
7. U.S. Food and Drug Administration. (2015). Abbreviated new drug application approvals and patent certifications under the Hatch-Waxman Act.